Rating:
Outperform
ENTA
105.22 %
Enanta Pharmaceuticals Inc. (ENTA) rated Outperform by Credit Suisse
Credit Suisse rated Outperform Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) on 04/15/2013, when the stock price was $20.48. Since
then, Enanta Pharmaceuticals Inc. has gained 105.22% as of 01/27/2016's recent price of $42.03. If you would have followed this Credit Suisse's recommendation on ENTA, you would have gained 105.22% of your investment in 1017 days.
Excellence in equity and fixed income research is a hallmark of
Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally,
Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.